Despite improvements in safety of plasma transfusion due to correct selection of the donors, performance of serological screening (HIV1-2, HTLV1-2, HCV, HBV, CMV, VDRL and TPHA) and nucleic acid testing (NAT) for HIV & HCV, some infectious transmissions, particularly virus transmissions still remain.These risks are due to the known major serologically screened viruses at the window period, unscreened viruses, undetectable viruses and also new, emerging, re-emerging, or mutated infectious agents resulting from the climatic, ecologic and sociologic changes and travels.In France, the estimation of risks for conventional virus transmission by blood labile products was performed by the health authority “afssaps” (J.Pillonel et all, 2009).